Back to results
US 10,517,924 B2Granted
High density lipoprotein nanoparticles for inflammation
AssigneeNorthwestern University
InventorsC. Shad Thaxton, Linda Foit
Life of this patent
Estimating the term…
Abstract
The invention in aspects relates to methods of treating sepsis using HDL-NP. The methods include the use of nanoparticles having a core and a lipid based shell with optimal lipids therein.
Claims23
A method for decreasing the severity of an endotoxin mediated immune response, comprising
- contacting an immune cell that has been exposed to an endotoxin with a high density lipoprotein (HDL) nanoparticle (HDL-NP), wherein the HDL-NP has a zeta potential of less than −30 mV, wherein the HDL-NP comprises a core surrounded by a lipid layer shell and an apolipoprotein, wherein the lipid layer includes at least one molecule of dipalmitoylphosphatidylcholine (DPPC) in an effective amount to decrease the severity of an endotoxin mediated immune response relative to an endotoxin mediated immune response in the absence of the HDL-NP, and wherein the HDL-NP lipid layer shell comprises an inner surface and an outer surface, wherein the lipids in the outer surface of the shell are comprised of 18:2 PG.
A method for treating sepsis, comprising
- administering to a subject having sepsis a high density lipoprotein (HDL) nanoparticle (HDL-NP), wherein the HDL-NP is less than 30 nm in diameter and comprises a core surrounded by a lipid layer shell and an apolipoprotein, wherein the lipid layer shell includes at least one molecule of Dipalmitoylphosphatidylcholine (DPPC) in an effective amount to treat sepsis, and wherein the HDL-NP lipid layer shell comprises an inner surface and an outer surface, wherein the lipids in the outer surface of the shell are comprised of 18:2 PG.
A method for treating sepsis, comprising
- administering to a subject having sepsis a high density lipoprotein (HDL) nanoparticle (HDL-NP), wherein the HDL-NP comprises a core surrounded by a lipid layer shell and an apolipoprotein, and wherein the HDL-NP is administered in a HDL sub-therapeutic dose effective to treat sepsis, wherein the HDL-NP in the HDL sub-therapeutic dose is less than a molar equivalent of the free HDL or recombinant HDL, or wherein the HDL sub-therapeutic dose does not result in a therapeutic response for free HDL or recombinant HDL, and wherein the HDL-NP lipid layer shell comprises an inner surface and an outer surface, wherein the lipids in the outer surface of the shell are comprised of 18:2 PG.
A method for decreasing the severity of an endotoxin mediated immune response, comprising
- contacting an immune cell that has been exposed to an endotoxin with a high density lipoprotein (HDL) nanoparticle (HDL-NP), wherein the HDL-NP has a zeta potential of less than −30 mV, wherein the HDL-NP comprises a core surrounded by a lipid layer shell and an apolipoprotein, and wherein the lipid layer includes at least one molecule of cardiolipin, phosphatidylethanolamine (PE), dipalmitoylphosphatidylcholine (DPPC), and phosphatidylglycerol (PG), in an effective amount to decrease the severity of an endotoxin mediated immune response relative to an endotoxin mediated immune response in the absence of the HDL-NP, wherein the lipid layer shell has an inner surface and an outer surface, wherein at least 80% of the lipids in the outer surface of the shell are PG or cardiolipin, and wherein the HDL-NP lipid layer shell comprises an inner surface and an outer surface, wherein the lipids in the outer surface of the shell are comprised of 18:2 PG.
Dependencies are inferred from the claim text.